Add BrightSurf on Google Email

Journal of the National Cancer Institute


Genetic manifestation of melanoma linked to geographic location

A study found that genetic mutation penetrance for melanoma varies by geographic location, with higher risks in countries like the US and Australia. Researchers suggest environmental factors contribute to this variation, contradicting previous assumptions about gene mutations and their impact on disease expression.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJun 18, 2002

Studies call for quality assurance in selecting candidates for herceptin trials

Two studies found high discordance between local laboratory tests and central testing facilities, raising concerns about patient eligibility for trastuzumab trials. These discrepancies could lead to unnecessary costs and cardiotoxicity. Trials have since modified their criteria to require central laboratory testing to confirm HER2 status.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJun 4, 2002

Other highlights in the May 15 issue of JNCI

Research findings link insulin-like growth factor I (IGF-I) to decreased lung cancer risk when bound by IGFBP-3. Environmental factors influence DNA methylation patterns in tumor suppressor genes, which may impact cancer incidence. Electro-gene therapy enhances IL-12 protein delivery, triggering long-lasting antitumor responses.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMay 14, 2002

Other highlights in the May 1 issue of JNCI

Researchers found that premenopausal women who underwent mastectomy alone had similar survival outcomes regardless of the menstrual cycle phase. In contrast, those who received adjuvant oophorectomy and tamoxifen during the luteal phase experienced better disease-free and overall survival rates. Additionally, studies suggest socioecono...

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateApr 30, 2002

Other highlights in the April 17 issue of JNCI

A new study has found that women with the highest levels of sex hormones are at roughly twice the risk of developing breast cancer compared to those with lower levels. Additionally, researchers have discovered a potential therapy for glioblastomas using a fusion protein that shows little toxicity. Reproductive hormones have also been l...

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateApr 16, 2002

Hormone replacement therapy may be associated with increased ovarian cancer risk

A new study found that hormone replacement therapy, particularly estrogen alone, may increase the risk of epithelial ovarian cancer in postmenopausal women with an intact uterus. Women who used sequential progestins with estrogens had a higher risk of developing ovarian cancer compared to those who never used HRT.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateApr 2, 2002

Racial and ethnic minorities may receive less appropriate cancer treatment

A recent study found racial and ethnic disparities in the receipt of cancer treatments, with white patients often receiving more aggressive therapy than minority groups. The study analyzed data from 87 studies and found consistent differences in therapy, including less frequent surgery for lung and colorectal cancers among minorities.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMar 5, 2002

Other highlights in the Feb. 20 issue of JNCI

African-American patients with non-small-cell lung cancer have a significantly lower one-year survival rate compared to non-African-American patients. Despite similar disease stages and health care disparities, researchers found no difference in outcomes after adjusting for factors such as performance status and socioeconomic status.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateFeb 19, 2002

Misclassification of death may influence perceived value of cancer screening

A study found that two forms of bias in cause-of-death classification affect the results of randomized trials on cancer screening. Sticky-diagnosis bias biases against screening, while slippery-linkage bias biases in favor of screening. The authors suggest using all-cause mortality to accurately assess the value of screening.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateFeb 5, 2002

Other highlights in the Feb. 6 issue of JNCI

Researchers found that response rates, survival rates, and quality-of-life outcomes are similar between elderly patients (ages 70+) and younger patients with non-small-cell lung cancer. Additionally, studies report an increased risk of lung cancer after Hodgkin's disease treatment, especially in smokers, and analyzed cost-effectiveness...

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateFeb 5, 2002

Tanning devices may contribute to incidence of common skin cancers

A new study found that individuals who used tanning devices were 2.5 times more likely to develop squamous cell carcinoma and 1.5 times more likely to develop basal cell carcinoma compared to those who did not use them. The risk of these cancers increased with the age at which participants started using tanning devices.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateFeb 5, 2002

Other highlights in the Jan. 16 issue of JNCI

Researchers investigate DNA repair capacity and its association with melanoma risk, while also exploring the predictive value of HPV testing in managing equivocal Pap tests. Additionally, a study on breast cancer biomarkers finds that measuring uPA and PAI-1 levels may help predict disease course and inform treatment strategies.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJan 15, 2002

New method for anticancer drug discovery developed

Researchers at the Fred Hutchinson Cancer Research Center have developed a new cell-based approach for anticancer drug discovery, which identified 39 new compounds selective for yeast cells with faulty DNA repair enzymes. This approach is adaptable to high-throughput screening methods and complements target-based screening, potentially...

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJan 15, 2002

Differences in nicotine metabolism may explain ethnic variations in lung cancer rates

A study found that Chinese-Americans take in less nicotine per cigarette and metabolize it more slowly than whites and Latinos, possibly explaining lower lung cancer rates. This correlation suggests slow nicotine metabolism may contribute to reduced nicotine intake, a factor linked to lower lung cancer incidence.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJan 15, 2002

Other highlights in the Jan. 2 issue of JNCI

Researchers have identified matrix metalloproteinases as a key player in the spread of prostate cancer to the bone, offering a new target for treatment. Additionally, a genetic marker may be useful in predicting survival rates for patients with diffuse large B-cell lymphoma, while oral contraceptive use has been found to reduce ovarian...

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJan 1, 2002

Progestin in oral contraceptives associated with lower risk of ovarian cancer

A new study analyzing oral contraceptive use among women with epithelial ovarian cancer found a significant association between progestin levels and reduced risk. Women using low-progestin/high-estrogen contraceptives were more likely to develop ovarian cancer compared to those using high-progestin/high-estrogen contraceptives.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJan 1, 2002